GlassScriptPhysician profile
Hossein Shenasa
NPI 1942368444
$20,394.07
in general payments reported to CMS, 2019-2025
25 companies · $2,767 in 2025
The $2,767 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,812 · 2020: $391 · 2021: $1,059 · 2022: $4,080 · 2023: $3,962 · 2024: $4,323 · 2025: $2,767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $7,300 · Food and Beverage: $3,752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $7,299.63 |
| Food and Beverage | $3,752.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $9,494.43 | 2019-2024 | Selectra, Rivacor 7 Dr-T, Acticor 7 Vr-T Dx |
| Medtronic, INC. | $3,224.42 | 2021-2025 | Evera Mri Xt Dr Surescan, Micra, Aurora Ev-Icd Mri Surescan |
| Boston Scientific Corporation | $2,481.71 | 2021-2025 | Watchman Access System, Watchman Flx |
| Amarin Pharma, INC. | $1,205.29 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $960.82 | 2019-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $410.12 | 2019-2023 | Xarelto |
| Akcea Therapeutics, INC. | $404.20 | 2019-2020 | |
| Pfizer INC. | $336.76 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $289.58 | 2019-2023 | |
| Philips North America LLC | $286.47 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $270.62 | 2019-2023 | Jardiance |
| Medical Device Business Services, INC. | $217.88 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $150.00 | 2025 | |
| Vifor Pharma, INC. | $111.19 | 2019 | |
| Merck Sharp & Dohme LLC | $110.46 | 2022-2025 | Verquvo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $75.41 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $72.53 | 2020-2023 | |
| Bardy Diagnostics, INC. | $48.09 | 2022 | |
| Abbott Laboratories | $45.17 | 2020-2024 | Gallant |
| Biosense Webster, INC. | $40.00 | 2023 | Soundstar, Carto 3 |
| Astrazeneca Pharmaceuticals LP | $38.44 | 2019-2023 | Farxiga |
| Cardiva Medical, INC. | $33.88 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Medtronic Vascular, INC. | $33.41 | 2019-2020 | |
| Baxter Healthcare | $27.18 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $26.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hossein Shenasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.